As such, our findings that Vipr2ΔILC3 mice under an HFD maintain higher levels of IL-22 production by ILC3 in comparison to WT littermate control mice and concurrently have reduced liver steatosis suggest immune-metabolic interactions are an important therapeutic avenue worth further investigating in MASLD. The gene discussed is IL22; the disease is Hepatic steatosis.